Dr Damian Holsinger

Lecturer in Neuroscience
Biomedical Sciences, School of Medical Sciences

Telephone +61 2 9351 9324 (or 0876)
Fax +61 2 9351 9520

Map

Biographical details

Damian Holsinger began investigating molecular mechanisms underlying Alzheimer's disease in 1997. In 2002 he made the seminal discovery that levels of the pivotal AD-related enzyme, BACE1, were increased in the brain of patients (Annals of Neurology, 51:783-786). These findings have been widely accepted in the field (325 citations) and have led to a concentrated focus on this enzyme as a therapeutic avenue for the treatment of Alzheimer's disease. In 2006, Damian accepted a position as Lecturer in Neuroscience at The University of Sydney and founded the Laboratory of Molecular Neuroscience at the Brain & Mind Research Institute in 2007. He continues to investigate molecular mechanisms underlying neurodegenerative diseases with a particular focus on BACE1.

Research interests

Research interests surround the understanding of mechanisms by which complex neurological disorders arise and methods of treating these diseases.

Teaching and supervision

Neuroanatomy, Neurophysiology, Neuropathology, Neuroplasticity, Neuromolecular Medicine, Molecular Biology, Molceular and Cellular Neuroscience

Selected grants

2012

  • Bruker Daltonics autoflex speed MALDI-TOF/TOF mass spectrometer; Baxter R, Halliday G, Marsh D, Gill A, Clarke S, Smith R, Little C, Jackson C, O'Neill C, Murphy C, Sharland A, Chadban S, Mason R, Assinder S, Verdurand M, Richardson D, Machaalani R, Hambly B, Chan-Ling T, Dos Remedios C, Holsinger D, Lay P; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2009

  • in vivo regulation of the Alzheimers disease beta-secretase, BACE1; Holsinger D; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Development of a system for the delivery of therapeutics across the blood-brain barrier; Holsinger D; Rebecca L Cooper Medical Research Foundation/Equipment Grant.
  • Hidex Chameleon V Multi-Technology plate reader; Ittner L, Goetz J, MacDonald C, Kassiou M, Connor M, Holsinger D; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2008

  • Research Infrastructure (Major Equipment) Scheme 2008; Ittner L, Goetz J, Christie M, Bennett M, Kassiou M, Connor M, Holsinger D, Bagley E; Faculty of Medicine/Linkage Infrastructure, Equipment and Facilities (LIEF).

2007

  • Identifying molecular associations with the Alzheimer's disease beta-secretase enzyme, BACE1; Holsinger D; Clive & Vera Ramaciotti Foundation/Clive & Vera Ramaciotti Fndtn.

2005

  • Characterization of Alzheimer's disease β-secretase protein isoforms in human brain; Holsinger D; Bethlehem Griffiths Research Foundation/Project Grant.
  • Evaluating the Alzheimer's disease β-secretase enzyme, BACE, as a diagnostic marker; Holsinger D; University of Melbourne/Early Career Researcher Development Award.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Evin, G., Sernee, M., Barnham, K., Holsinger, R., Culvenor, J., Hoke, D., Li, Q., et al (2002). Modulation of Alzheimer’s disease Aβ pathways for rational therapeutic intervention: secretase inhibition and metalloprotein active compounds. In K. Iqbal and B Winblad (Eds.), Alzheimer’s disease and related disorders: Research advances, (pp. 513-523). Bucharest, Romania: "Ana Alsan" International Academy of Aging.

Journals

  • Sajjan, S., Holsinger, D., Fok, S., Ebrahimkhani, S., Rollo, J., Banati, R., Graeber, M. (2014). Up-regulation of matrix metallopeptidase 12 in motor neurons undergoing synaptic stripping. Neuroscience, 274, 331-340. [More Information]
  • Buljan, V., Holsinger, D., Hambly, B., Banati, R., Ivanova, E. (2013). Intrinsic microtubule GTP-cap dynamics in semi-confined systems: kinetochore-microtubule interface. Journal of Biological Physics, 39(1), 81-98. [More Information]
  • Kosaraju, J., Gali, C., Khatwal, R., Dubala, A., Chinni, S., Holsinger, D., Madhunapantula, V., Nataraj, S., Basavan, D. (2013). Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology, 72, 291-300. [More Information]
  • Buljan, V., Holsinger, D., Brown, D., Bohorquez-Florez, J., Hambly, B., Delikatny, E., Ivanova, E., Banati, R. (2013). Spinodal decomposition and the emergence of dissipative transient periodic spatio-temporal patterns in acentrosomal microtubule multitudes of different morphology. Chaos, 23(2), 1-16. [More Information]
  • Holsinger, D., Goense, N., Bohorquez-Florez, J., Strappe, P. (2013). Splice variants of the Alzheimer’s disease beta-secretase, BACE1. Neurogenetics, 14(1), 1-9. [More Information]
  • Li, W., Holsinger, D., Kruse, C., Flugel, A., Graeber, M. (2013). The Potential for Genetically Altered Microglia to Influence Glioma Treatment. CNS & Neurological Disorders - Drug Targets, 12(6), 750-762. [More Information]
  • Holsinger, D., Brown, R., Richmond, R., Kay-Lambkin, F., Kirby, A., Chan, D. (2012). Prevalence of the long-allele genotype of the serotonin transporter-linked gene in female centenarians. Journal of the American Geriatrics Society, 60(9), 1786-1788. [More Information]
  • George, A., Gordon, L., Beissbarth, T., Koukoulas, I., Holsinger, D., Perreau, V., Cappai, R., Tan, S., Masters, C., Scott, H., et al (2010). A Serial Analysis of Gene Expression Profile of the Alzheimer's Disease Tg2576 Mouse Model. Neurotoxicity Research, 17, 360-379. [More Information]
  • Kassiou, M., Banati, R., Holsinger, D., Meikle, S. (2009). Challenges in molecular imaging of Parkinson's disease: A brief overview. Brain Research Bulletin, 78(2-3), 105-108. [More Information]
  • Einfeld, S., Goetz, J., Holsinger, D. (2008). Pathogenetic mechanisms in Down Syndrome. Journal of Intellectual Disability Research, 52(10), 813-813. [More Information]
  • Einfeld, S., Goetz, J., Holsinger, R. (2008). Two novel genes associated with Down’s syndrome. Journal of Intellectual Disability Research, 52(10), 813.
  • White, A., Du, T., Laughton, K., Volitakis, I., Sharples, R., Hoke, D., Holsinger, R., Evin, G., Cherny, R., Hill, A., et al (2006). Clioquinol induces metal-dependent degradation of the Alzheimer's disease amyloid beta peptide by up-regulation of matrix metalloproteases. Journal of Neurochemistry, 98(90).
  • Holsinger, D., Lee, J., Boyd, A., Masters, C., Collins, S. (2006). CSF BACE1 activity is increased in CJD and Alzheimer disease other dementias. Neurology, 67(4), 710-712. [More Information]
  • George, A., Holsinger, D., McLean, C., Tan, S., Scott, H., Cardamone, T., Cappai, R., Masters, C., Li, Q. (2006). Decreased phosphatidylethanolamine binding protein expression correlates with Aβ accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology, 27(4), 614-623. [More Information]
  • White, A., Du, T., Laughton, K., Volitakis, I., Sharples, R., Xilinas, M., Hoke, D., Holsinger, D., Evin, G., Cherny, R., et al (2006). Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. Journal of Biological Chemistry, 281(26), 17670-17680. [More Information]
  • Beckman, M., Holsinger, D., Small, D. (2006). Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. Biochemistry, 45(21), 6703-6714. [More Information]
  • Mok, S., Holsinger, R., Li, Q., Cappai, R., Masters, C., Culvenor, J. (2005). Alpha-synuclein mutations increase sensitivity of human neuroblastoma cells to cytotoxicity. Journal of Neurochemistry, 94, 118-118.
  • Holsinger, R., McLean, C., Masters, C., Evin, G. (2004). Analysis of BACE protein and activity in human cerebrospinal fluid. Neurobiology of Aging, 25, 528-528.
  • George, A., Holsinger, D., McLean, C., Laughton, K., Beyreuther, K., Evin, G., Masters, C., Li, Q. (2004). APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiology of Disease, 16(1), 124-132. [More Information]
  • Evin, G., Canterford, L., Hoke, D., Holsinger, R., Culvenor, J., Masters, C. (2004). Gamma-secretase inhibitors stabilize a 900 KDA presenilin complex: A tetrameric model for gamma-secretase. Neurobiology of Aging, 25, 558-558. [More Information]
  • Holsinger, D., McLean, C., Collins, S., Masters, C., Evin, G. (2004). Increased β-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Annals of Neurology, 55(6), 898-899. [More Information]
  • Evin, G., Zhu, A., Holsinger, D., Masters, C., Li, Q. (2003). Proteolytic processing of the Alzheimer's Disease amyloid precursor protein in brain and platelets. Journal of Neuroscience Research, 74, 386-392. [More Information]
  • Evin, G., Holsinger, R., Canterford, L., Hoke, D., Masters, C., Eggert, S., Weidemann, A., Beyreuther, K. (2002). APP C-terminal fragments in Alzheimer's disease brain. Neurobiology of Aging, 23(1), 656.
  • Holsinger, R., McLean, C., Masters, C., Evin, G., Beyreuther, K. (2002). BACE and beta-secretase product CTF beta are increased in sporadic Alzheimer's disease brain. Neurobiology of Aging, 23(1), 663.
  • Evin, G., Holsinger, R., Eggert, S., Weidmann, A., Canterford, L., Hoke, D., Gandy, S., McLean, C., Beyreuther, K., Masters, C. (2002). Carboxyl-terminal fragments of the amyloid precursor protein in Alzheimer’s disease brain: detection of γ-secretase products. Brain Aging International Journal, 29(3), 61-66.
  • Holsinger, D., McLean, C., Beyreuther, K., Masters, C., Evin, G. (2002). Increased expression of the amyloid precursor beta secretase in Alzheimer's Disease. Annals of Neurology, 51(6), 783-786. [More Information]
  • Fahnestock, M., Garzon, D., Holsinger, D., Michalski, B. (2002). Neurotrophic factors and Alzheimer's disease: are we focusing on the wrong molecule? Journal of Neural Transmission, 62(suppl.), 239-252.
  • Evin, G., Sharples, R., Weidemann, A., Reinhard, F., Carbone, V., Culvenor, J., Holsinger, D., Sernee, M., Beyreuther, K., Masters, C. (2001). Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease. Biochemistry, 62, 239-250.
  • Holsinger, R., Schnarr, J., Henry, P., Castelo, V., Fahnestock, M. (2000). Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Molecular Brain Research, 76(2), 347-354.

Conferences

  • Holsinger, D., Petersen, G., Hilbert, B., Strappe, P. (2013). Generation of induced neuronal cells from adult stem cells for tissue engineering applications by lentiviral vector expression of transcription factors. Australian Society of Biomaterials and Tissue Engineering (ASBTE), Tanunda, Barossa Valley, South Australia: ASBTE.
  • Sajjan, S., Holsinger, D., Fok, S., Banati, R., Greaber, M. (2013). Up-regulation of matrix metallopeptidase 12 in motor neurons undergoing synaptic stripping. Sydney Neuroscience Network, Neuroscience and Mental Health Symposium, Sydney, NSW.
  • Holsinger, D., Chua, Y., Goense, N., Alomari, M., Rao, G., Bohorquez, J., Chen, Y. (2012). A novel BACE1-regulating protein with therapeutic potential. Alzheimer’s Association Internatonal Conference 2012, Vancouver, Canada.: Alzheimer’s Association Internatonal Conference 2012.
  • Holsinger, D., Li, W., Graeber, M. (2012). Microglia as a therapeutic target in glioma. Personalised Medicine Workshop - HMRI, University of Newcastle NSW: Personalised Medicine Workshop HMRI.
  • Holsinger, D., Li, W., Garebar, M. (2012). The need for multidimensional tissue analysis: Alzheimer's disease as an example. Biomarker Discovery Conference 2012, Shoal Bay NSW: Biomarker Discovery Conference 2012.
  • Holsinger, D., Alomari, M. (2008). An endogenous regulator decreases levels of the Alzheimer’s disease BACE1. Society of Neuroscience Abstract, Washington DC USA: Society of Neuroscience Abstract.
  • George, A., Gordon, L., Beissbarth, T., Koukoulase, L., Holsinger, R., Perreaua, V., Cappai, R., Tan, S., Masters, C., Scott, H., et al (2006). A Serial Analysis of Gene Expression (SAGE) profile of the Alzheimer’s disease Tg2576 mouse model. The 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid, Spain: The 10th International Conference on Alzheimer’s Disease and Related Disorders.
  • Small, D., Holsinger, R., Beckman, M. (2006). Heparin activates β-secertase (BACE1) of Alzheimer’s disease and increases autocatalysis of the enzyme. The 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid, Spain: The 10th International Conference on Alzheimer’s Disease and Related Disorders.
  • Mok, S., Holsinger, R., Li, Q., Cappai, R., Masters, C., Culvenor, J. (2005). Effect of pathogenic alpha-synucleain mutations on sensitivity of human neuroblastoma cells to toxicity. 7th International Conference AD/PD, Sorrento, Italy: 7th International Conference AD/PD.
  • Holsinger, R., Saez-Valero, J., Lee, J., Collins, S., Masters, C., Evin, G. (2005). Evaluating BACE 1 as a diagnostic marker for Alzheimer’s disease. 7th International Conference AD/PD, Sorrento, Italy: 7th International Conference AD/PD.
  • Chua, Y., Helfenbaum, L., Masters, C., Evin, G., Holsinger, R. (2005). Identification of Proteins Interacting with the Alzheimer’s Disease β-secretase Enzyme, BACE1. Society of Neuroscience Abstract, Washington DC USA: Society of Neuroscience Abstract.
  • White, A., Du, T., Hill, A., Sharples, R., Barnham, K., Holsinger, R., Ciccotosto, G., Hoke, D., Evin, G., Laughton, K., et al (2005). Modulation of APP and Aβ metabolism by metal chelators. ISN and ESN 20th Biennial Meeting, Insbruck, Austria: ISN and ESN 20th Biennial Meeting.
  • Holsinger, R., Tan, N., Masters, C., Evin, G., Tan, J. (2005). Suppression of the Alzheimer’s disease BACE1 by RNA interference. Society of Neuroscience Abstract, Washington DC USA: Society of Neuroscience Abstract.
  • George, A., Holsinger, R., McLean, C., Laughton, K., Evin, G., Masters, C., Li, Q. (2004). Dietary cholesterol regulates APP processing in the Alzheimer's transgenic mouse model. Australian Neuroscience Society, Melbourne, Victoria Australia: Australian Neuroscience Society.
  • Evin, G., Canterford, L., Holsinger, R., Masters, C. (2003). Analysis of Alzheimer's Disease gamma-Secretase Complex Using Biotinylated Inhibitors. International Conference on Aspartic Proteases and Inhibitors, Kyoto, Japan.: International Conference on Aspartic Proteases and Inhibitors.
  • Holsinger, R., Chua, Y., Masters, C., Evin, G. (2003). Detection of the Alzheimer’s disease β secretase enzyme, BACE, using different extraction techniques. Society for Neuroscience Abstracts 2003, New Orleans, USA: Society for Neuroscience Abstract.
  • Evin, G., Culvenor, J., Sernee, M., Hoke, D., Canterford, L., Holsinger, R., Cappai, R., Beyreuther, K., Masters, C. (2003). Gamma-secretase processing of APP transmembravpmne domain. 6th International Conference AD/PD, Seville, Spain: 6th International Conference AD/PD.
  • Holsinger, R., Cullen, K., Culvenor, J., Roytta, K., Canterford, L., Masters, C., Evin, G. (2003). Redefinition of BACE1 transmembrane domain to include residues 455-460. International Conference on Aspartic Proteases and Inhibitors, Kyoto, Japan.: International Conference on Aspartic Proteases and Inhibitors.
  • Holsinger, R., Cullen, K., Culvenor, J., Roytta, K., Masters, C., Evin, G. (2003). Redefinition of BACE1 transmembrane domain to include residues 455-460. 28th Lorne Conference on Protein Structure and Function, Victoria, Australia: 28th Lorne Conference on Protein Structure and Function.
  • George, A., Holsinger, R., McLean, C., Laughton, K., Beyreuther, K., Evin, G., Masters, C., Li, Q. (2003). Regulation of APP processing in the Alzheimer’s transgenic mouse model with diet-induced hypercholesterolemia. Combio 2003 ASBMB, Melbourne, Australia: Combio 2003 ASBMB.
  • Holsinger, R., McLean, C., Beyreuther, K., Masters, C., Evin, G. (2001). Increased BACE Immunoreactivity in Alzheimer’s Disease Brain. Society for Neuroscience Abstract 2001, San Diego, USA: Society for Neuroscience Abstract 2001.
  • Holsinger, R., Cappai, R., McLean, C., Smith, M., Reinhard, F., Multhaup, G., Weidemann, A., Beyreuther, K., Masters, C., Evin, G. (2000). Quantitative analysis of BACE1 in normal and Alzheimer’s disease brain. Society for Neuroscience Abstract 2000, New Orleans USA: Society for Neuroscience Abstract 2000.

2014

  • Sajjan, S., Holsinger, D., Fok, S., Ebrahimkhani, S., Rollo, J., Banati, R., Graeber, M. (2014). Up-regulation of matrix metallopeptidase 12 in motor neurons undergoing synaptic stripping. Neuroscience, 274, 331-340. [More Information]

2013

  • Holsinger, D., Petersen, G., Hilbert, B., Strappe, P. (2013). Generation of induced neuronal cells from adult stem cells for tissue engineering applications by lentiviral vector expression of transcription factors. Australian Society of Biomaterials and Tissue Engineering (ASBTE), Tanunda, Barossa Valley, South Australia: ASBTE.
  • Buljan, V., Holsinger, D., Hambly, B., Banati, R., Ivanova, E. (2013). Intrinsic microtubule GTP-cap dynamics in semi-confined systems: kinetochore-microtubule interface. Journal of Biological Physics, 39(1), 81-98. [More Information]
  • Kosaraju, J., Gali, C., Khatwal, R., Dubala, A., Chinni, S., Holsinger, D., Madhunapantula, V., Nataraj, S., Basavan, D. (2013). Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology, 72, 291-300. [More Information]
  • Buljan, V., Holsinger, D., Brown, D., Bohorquez-Florez, J., Hambly, B., Delikatny, E., Ivanova, E., Banati, R. (2013). Spinodal decomposition and the emergence of dissipative transient periodic spatio-temporal patterns in acentrosomal microtubule multitudes of different morphology. Chaos, 23(2), 1-16. [More Information]
  • Holsinger, D., Goense, N., Bohorquez-Florez, J., Strappe, P. (2013). Splice variants of the Alzheimer’s disease beta-secretase, BACE1. Neurogenetics, 14(1), 1-9. [More Information]
  • Li, W., Holsinger, D., Kruse, C., Flugel, A., Graeber, M. (2013). The Potential for Genetically Altered Microglia to Influence Glioma Treatment. CNS & Neurological Disorders - Drug Targets, 12(6), 750-762. [More Information]
  • Sajjan, S., Holsinger, D., Fok, S., Banati, R., Greaber, M. (2013). Up-regulation of matrix metallopeptidase 12 in motor neurons undergoing synaptic stripping. Sydney Neuroscience Network, Neuroscience and Mental Health Symposium, Sydney, NSW.

2012

  • Holsinger, D., Chua, Y., Goense, N., Alomari, M., Rao, G., Bohorquez, J., Chen, Y. (2012). A novel BACE1-regulating protein with therapeutic potential. Alzheimer’s Association Internatonal Conference 2012, Vancouver, Canada.: Alzheimer’s Association Internatonal Conference 2012.
  • Holsinger, D., Li, W., Graeber, M. (2012). Microglia as a therapeutic target in glioma. Personalised Medicine Workshop - HMRI, University of Newcastle NSW: Personalised Medicine Workshop HMRI.
  • Holsinger, D., Brown, R., Richmond, R., Kay-Lambkin, F., Kirby, A., Chan, D. (2012). Prevalence of the long-allele genotype of the serotonin transporter-linked gene in female centenarians. Journal of the American Geriatrics Society, 60(9), 1786-1788. [More Information]
  • Holsinger, D., Li, W., Garebar, M. (2012). The need for multidimensional tissue analysis: Alzheimer's disease as an example. Biomarker Discovery Conference 2012, Shoal Bay NSW: Biomarker Discovery Conference 2012.

2010

  • George, A., Gordon, L., Beissbarth, T., Koukoulas, I., Holsinger, D., Perreau, V., Cappai, R., Tan, S., Masters, C., Scott, H., et al (2010). A Serial Analysis of Gene Expression Profile of the Alzheimer's Disease Tg2576 Mouse Model. Neurotoxicity Research, 17, 360-379. [More Information]

2009

  • Kassiou, M., Banati, R., Holsinger, D., Meikle, S. (2009). Challenges in molecular imaging of Parkinson's disease: A brief overview. Brain Research Bulletin, 78(2-3), 105-108. [More Information]

2008

  • Holsinger, D., Alomari, M. (2008). An endogenous regulator decreases levels of the Alzheimer’s disease BACE1. Society of Neuroscience Abstract, Washington DC USA: Society of Neuroscience Abstract.
  • Einfeld, S., Goetz, J., Holsinger, D. (2008). Pathogenetic mechanisms in Down Syndrome. Journal of Intellectual Disability Research, 52(10), 813-813. [More Information]
  • Einfeld, S., Goetz, J., Holsinger, R. (2008). Two novel genes associated with Down’s syndrome. Journal of Intellectual Disability Research, 52(10), 813.

2006

  • George, A., Gordon, L., Beissbarth, T., Koukoulase, L., Holsinger, R., Perreaua, V., Cappai, R., Tan, S., Masters, C., Scott, H., et al (2006). A Serial Analysis of Gene Expression (SAGE) profile of the Alzheimer’s disease Tg2576 mouse model. The 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid, Spain: The 10th International Conference on Alzheimer’s Disease and Related Disorders.
  • White, A., Du, T., Laughton, K., Volitakis, I., Sharples, R., Hoke, D., Holsinger, R., Evin, G., Cherny, R., Hill, A., et al (2006). Clioquinol induces metal-dependent degradation of the Alzheimer's disease amyloid beta peptide by up-regulation of matrix metalloproteases. Journal of Neurochemistry, 98(90).
  • Holsinger, D., Lee, J., Boyd, A., Masters, C., Collins, S. (2006). CSF BACE1 activity is increased in CJD and Alzheimer disease other dementias. Neurology, 67(4), 710-712. [More Information]
  • George, A., Holsinger, D., McLean, C., Tan, S., Scott, H., Cardamone, T., Cappai, R., Masters, C., Li, Q. (2006). Decreased phosphatidylethanolamine binding protein expression correlates with Aβ accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology, 27(4), 614-623. [More Information]
  • White, A., Du, T., Laughton, K., Volitakis, I., Sharples, R., Xilinas, M., Hoke, D., Holsinger, D., Evin, G., Cherny, R., et al (2006). Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. Journal of Biological Chemistry, 281(26), 17670-17680. [More Information]
  • Beckman, M., Holsinger, D., Small, D. (2006). Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. Biochemistry, 45(21), 6703-6714. [More Information]
  • Small, D., Holsinger, R., Beckman, M. (2006). Heparin activates β-secertase (BACE1) of Alzheimer’s disease and increases autocatalysis of the enzyme. The 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid, Spain: The 10th International Conference on Alzheimer’s Disease and Related Disorders.

2005

  • Mok, S., Holsinger, R., Li, Q., Cappai, R., Masters, C., Culvenor, J. (2005). Alpha-synuclein mutations increase sensitivity of human neuroblastoma cells to cytotoxicity. Journal of Neurochemistry, 94, 118-118.
  • Mok, S., Holsinger, R., Li, Q., Cappai, R., Masters, C., Culvenor, J. (2005). Effect of pathogenic alpha-synucleain mutations on sensitivity of human neuroblastoma cells to toxicity. 7th International Conference AD/PD, Sorrento, Italy: 7th International Conference AD/PD.
  • Holsinger, R., Saez-Valero, J., Lee, J., Collins, S., Masters, C., Evin, G. (2005). Evaluating BACE 1 as a diagnostic marker for Alzheimer’s disease. 7th International Conference AD/PD, Sorrento, Italy: 7th International Conference AD/PD.
  • Chua, Y., Helfenbaum, L., Masters, C., Evin, G., Holsinger, R. (2005). Identification of Proteins Interacting with the Alzheimer’s Disease β-secretase Enzyme, BACE1. Society of Neuroscience Abstract, Washington DC USA: Society of Neuroscience Abstract.
  • White, A., Du, T., Hill, A., Sharples, R., Barnham, K., Holsinger, R., Ciccotosto, G., Hoke, D., Evin, G., Laughton, K., et al (2005). Modulation of APP and Aβ metabolism by metal chelators. ISN and ESN 20th Biennial Meeting, Insbruck, Austria: ISN and ESN 20th Biennial Meeting.
  • Holsinger, R., Tan, N., Masters, C., Evin, G., Tan, J. (2005). Suppression of the Alzheimer’s disease BACE1 by RNA interference. Society of Neuroscience Abstract, Washington DC USA: Society of Neuroscience Abstract.

2004

  • Holsinger, R., McLean, C., Masters, C., Evin, G. (2004). Analysis of BACE protein and activity in human cerebrospinal fluid. Neurobiology of Aging, 25, 528-528.
  • George, A., Holsinger, D., McLean, C., Laughton, K., Beyreuther, K., Evin, G., Masters, C., Li, Q. (2004). APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiology of Disease, 16(1), 124-132. [More Information]
  • George, A., Holsinger, R., McLean, C., Laughton, K., Evin, G., Masters, C., Li, Q. (2004). Dietary cholesterol regulates APP processing in the Alzheimer's transgenic mouse model. Australian Neuroscience Society, Melbourne, Victoria Australia: Australian Neuroscience Society.
  • Evin, G., Canterford, L., Hoke, D., Holsinger, R., Culvenor, J., Masters, C. (2004). Gamma-secretase inhibitors stabilize a 900 KDA presenilin complex: A tetrameric model for gamma-secretase. Neurobiology of Aging, 25, 558-558. [More Information]
  • Holsinger, D., McLean, C., Collins, S., Masters, C., Evin, G. (2004). Increased β-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Annals of Neurology, 55(6), 898-899. [More Information]

2003

  • Evin, G., Canterford, L., Holsinger, R., Masters, C. (2003). Analysis of Alzheimer's Disease gamma-Secretase Complex Using Biotinylated Inhibitors. International Conference on Aspartic Proteases and Inhibitors, Kyoto, Japan.: International Conference on Aspartic Proteases and Inhibitors.
  • Holsinger, R., Chua, Y., Masters, C., Evin, G. (2003). Detection of the Alzheimer’s disease β secretase enzyme, BACE, using different extraction techniques. Society for Neuroscience Abstracts 2003, New Orleans, USA: Society for Neuroscience Abstract.
  • Evin, G., Culvenor, J., Sernee, M., Hoke, D., Canterford, L., Holsinger, R., Cappai, R., Beyreuther, K., Masters, C. (2003). Gamma-secretase processing of APP transmembravpmne domain. 6th International Conference AD/PD, Seville, Spain: 6th International Conference AD/PD.
  • Evin, G., Zhu, A., Holsinger, D., Masters, C., Li, Q. (2003). Proteolytic processing of the Alzheimer's Disease amyloid precursor protein in brain and platelets. Journal of Neuroscience Research, 74, 386-392. [More Information]
  • Holsinger, R., Cullen, K., Culvenor, J., Roytta, K., Canterford, L., Masters, C., Evin, G. (2003). Redefinition of BACE1 transmembrane domain to include residues 455-460. International Conference on Aspartic Proteases and Inhibitors, Kyoto, Japan.: International Conference on Aspartic Proteases and Inhibitors.
  • Holsinger, R., Cullen, K., Culvenor, J., Roytta, K., Masters, C., Evin, G. (2003). Redefinition of BACE1 transmembrane domain to include residues 455-460. 28th Lorne Conference on Protein Structure and Function, Victoria, Australia: 28th Lorne Conference on Protein Structure and Function.
  • George, A., Holsinger, R., McLean, C., Laughton, K., Beyreuther, K., Evin, G., Masters, C., Li, Q. (2003). Regulation of APP processing in the Alzheimer’s transgenic mouse model with diet-induced hypercholesterolemia. Combio 2003 ASBMB, Melbourne, Australia: Combio 2003 ASBMB.

2002

  • Evin, G., Holsinger, R., Canterford, L., Hoke, D., Masters, C., Eggert, S., Weidemann, A., Beyreuther, K. (2002). APP C-terminal fragments in Alzheimer's disease brain. Neurobiology of Aging, 23(1), 656.
  • Holsinger, R., McLean, C., Masters, C., Evin, G., Beyreuther, K. (2002). BACE and beta-secretase product CTF beta are increased in sporadic Alzheimer's disease brain. Neurobiology of Aging, 23(1), 663.
  • Evin, G., Holsinger, R., Eggert, S., Weidmann, A., Canterford, L., Hoke, D., Gandy, S., McLean, C., Beyreuther, K., Masters, C. (2002). Carboxyl-terminal fragments of the amyloid precursor protein in Alzheimer’s disease brain: detection of γ-secretase products. Brain Aging International Journal, 29(3), 61-66.
  • Holsinger, D., McLean, C., Beyreuther, K., Masters, C., Evin, G. (2002). Increased expression of the amyloid precursor beta secretase in Alzheimer's Disease. Annals of Neurology, 51(6), 783-786. [More Information]
  • Evin, G., Sernee, M., Barnham, K., Holsinger, R., Culvenor, J., Hoke, D., Li, Q., et al (2002). Modulation of Alzheimer’s disease Aβ pathways for rational therapeutic intervention: secretase inhibition and metalloprotein active compounds. In K. Iqbal and B Winblad (Eds.), Alzheimer’s disease and related disorders: Research advances, (pp. 513-523). Bucharest, Romania: "Ana Alsan" International Academy of Aging.
  • Fahnestock, M., Garzon, D., Holsinger, D., Michalski, B. (2002). Neurotrophic factors and Alzheimer's disease: are we focusing on the wrong molecule? Journal of Neural Transmission, 62(suppl.), 239-252.

2001

  • Evin, G., Sharples, R., Weidemann, A., Reinhard, F., Carbone, V., Culvenor, J., Holsinger, D., Sernee, M., Beyreuther, K., Masters, C. (2001). Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease. Biochemistry, 62, 239-250.
  • Holsinger, R., McLean, C., Beyreuther, K., Masters, C., Evin, G. (2001). Increased BACE Immunoreactivity in Alzheimer’s Disease Brain. Society for Neuroscience Abstract 2001, San Diego, USA: Society for Neuroscience Abstract 2001.

2000

  • Holsinger, R., Schnarr, J., Henry, P., Castelo, V., Fahnestock, M. (2000). Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Molecular Brain Research, 76(2), 347-354.
  • Holsinger, R., Cappai, R., McLean, C., Smith, M., Reinhard, F., Multhaup, G., Weidemann, A., Beyreuther, K., Masters, C., Evin, G. (2000). Quantitative analysis of BACE1 in normal and Alzheimer’s disease brain. Society for Neuroscience Abstract 2000, New Orleans USA: Society for Neuroscience Abstract 2000.

To update your profile click here. For support on your academic profile contact .